On 19 September, we will announce our Interim Results for the six months ended 30 June 2024. For details about our planned briefing for analysts, which will be hosted at the offices of Deutsche Numis and online, see: https://lnkd.in/eW5X4TkF
BenevolentAI
Biotechnology Research
London, Greater London 56,933 followers
Uniting human and machine intelligence to discover new ways to treat disease.
About us
BenevevolentAI is a global pioneer and leader in AI-augmented drug discovery. We serve patients by leveraging our proprietary and validated Benevolent Platform that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, Benevolent is well-positioned to identify and accelerate novel drug discoveries.
- Website
-
http://benevolent.com
External link for BenevolentAI
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- London, Greater London
- Type
- Public Company
- Founded
- 2013
- Specialties
- Artificial Intelligence, Drug Development, Scientific Innovation, Machine Learning, Deep Learning, Big Data, Pharmaceutical, BioPharma, and Drug Discovery
Locations
-
Primary
Maple Street
4-8
London, Greater London W1T 5HD, GB
-
1 Dock 72 Way
7th Floor
Brooklyn, New York NY 11205, US
-
Babraham Hall, Babraham,
Cambridge , Cambridgeshire CB22 3AT, GB
Employees at BenevolentAI
-
April Gibson
User Experience Leader
-
Juan Carlos Mobarec
Associate Director at AstraZeneca
-
Joerg Moeller, M.D.
Chief Executive Officer and Executive Director at BenevolentAI, Board Member, former EVP and Head of Global Research and Development at Bayer…
-
Jane McGuffog
VP Discovery, DMPK, Benevolent AI
Updates
-
We feature in The Times ‘Future Titans of UK AI’ series by Thomas Saunders, which includes an interview with our CEO, Joerg Moeller, M.D. ‘...[BenevolentAI] can point to real achievements in drug discovery. During the pandemic, it took the start-up only two days to identify baricitinib, a drug originally prescribed to treat rheumatoid arthritis, as a potential treatment for Covid. It soon received emergency approval from regulators in the United States and elsewhere. Like others in the drug discovery business, it has sought to demystify the black box that often characterises artificial intelligence. “Our focus is on what we are calling explainable AI,” Moeller said. “We want to use it in a very transparent fashion, where we have a track record of what we are doing in terms of the algorithm so that you’re always able to go back and trace back.”’
AI, new drugs and the appliance of life science
thetimes.com
-
We were pleased to join Matt Clifford at the Department for Science, Innovation and Technology to share insights for the AI Opportunities Action Plan. It’s vital the UK maximises its AI-driven productivity and investment, builds long-term infrastructure, and leverages its top-tier talent.
AI expert to lead Action Plan to ensure UK reaps the benefits of Artificial Intelligence
gov.uk
-
Our CEO, Joerg Moeller, M.D., shares his perspective on the current progress and future promise of AI-enabled drug discovery with Laith Al-Khalaf in The Sunday Times: “It takes more than ten years to bring a new drug to patients, at the average cost of $2.6 billion, and 90 per cent of these efforts still fail. The big promise of AI is to foundationally change that.”
AI discovers new drugs that could save millions of lives — and Big Pharma’s time
thetimes.com
-
Do you want to collaborate on cutting-edge, AI-driven drug discovery and development? We’d love to hear from you. Apply for a new role with our team in Cambridge or London: Advanced Machine Learning Engineer - https://lnkd.in/ejrMWUYA Director of Cheminfomatics and Computational Chemistry - https://lnkd.in/eNKuFFuY Senior Full Stack Software Engineer - https://lnkd.in/eCZ9UGNZ Senior Principal Cheminfomatics Data Scientist - https://lnkd.in/ef4DKsqB Senior Principal Toxicology Scientist - https://lnkd.in/ezDH4g6f Staff Engineer - https://lnkd.in/eFJYxVHJ
-
💡 Takeda’s Head of Innovation and Digital Technology, Nishtha Jain, explores the transformative impact of AI in pharmaceutical R&D alongside Anne Phelan, our Chief Scientific Officer. 👉 Hear the podcast from Emerj Artificial Intelligence Research: https://lnkd.in/dXq8dRnh
-
This AI Appreciation Day, like each day at BenevolentAI, we’re committed to explainability. As James Malone, our chief technology officer, says: “The aim of our technology is to serve patients with complex diseases. Our AI systems are designed to help scientists conduct research while ensuring trust and transparency. Our explainable AI provides evidence for decision-making, increases confidence in results and ensures that both the scientist and, ultimately, the patient are at the centre of what we do.” #AIAppreciationDay #EthicalAI
-
We’re very pleased to confirm that our General Counsel & Company Secretary, Will Scrimshaw, has been elected to techUK’s Main Board. With his extensive legal and policy experience, Will looks forward to contributing his expertise at this vital time for AI and technology development in the UK. Congratulations, Will!
-
The AI-driven drug discovery sector is reducing costs, increasing speed and improving precision in targeting and treating disease. Our chief scientific officer, Anne Phelan, spoke to Rachel Brazil for Pharmaceutical Journal Publications about: 👉 AI-powered discoveries: Identifying PDE10 as a novel target for ulcerative colitis and advancing BEN-8744 through early-phase clinical trials. 👉 Strategic collaborations: Joining forces with AstraZeneca and Merck Healthcare to accelerate the identification of promising drug candidates. 👉 Innovative NLP capabilities: Pioneering natural language processing tools to draw across the totality of biomedical data and uncover connections beyond human capacity. Read the full article here: https://lnkd.in/gBSNG_at
-
We have appointed Deutsche Numis as our Financial and Capital Markets Adviser, with immediate effect. Kenneth Mulvany, our Deputy Chair, comments: “We are pleased to appoint Deutsche Numis as our UK and pan-European corporate broker. We look forward to working with their team to maximise our capital markets strategy and realise the true value in BenevolentAI.” Contact details are available here: https://lnkd.in/eg6Z8qad
Appointment of Adviser
benevolent.com